       Immuno-Inflammatory
Overview
Immuno-inflammatory indications comprise a broad spectrum of diseases, which are characterized by disregulation of the body’s normal immune response. Steroids of the corticosteroid class are frequently prescribed for the treatment of many immuno-inflammatory diseases. The utility of these drugs, however, is limited by their substantial, dose-dependent, adverse side effects.
Zalicus’ clinical stage candidates for immuno-inflammatory diseases, Synavive® (CRx-102) and Prednisporin™ (FOV1101; licensed to Sanofi-Aventis/Fovea), are designed to leverage the potent immuno-modulatory activity of steroids with a novel mechanism enabling more potent activity at a lower dose for potentially reduced side effects compared to currently available treatments.
|